Experimental mRNA vaccine improves pancreatic cancer survival by 45%

In trials, use of the mRNA vaccine improved survival rates by 45% in patients with pancreatic cancer and melanoma, data that drove the development of this personalized medicine.

These data were provided by the Head of the Immunology Department of the Clinical Hospital of the University of Santiago de Compostela, Jose Gomez Rialduring the celebrations in Almeria XX International Vaccine Update Conference Balmis Knows

a meeting analyzed the results of new anti-cancer mRNA platforms.

Gómez Rial stressed that advances in immunotherapy and vaccines to treat cancer in recent years have provided “very promising” results, with phase II clinical trials showing a 45% improvement in survival rates for certain types of tumors, such as melanoma and pancreatic cancer. So far it has been very deadly.

“The immune system is a precision tool for cancer treatment,” the expert concluded. He believes that new messenger RNA platforms are a great hope because they can develop highly effective personalized vaccines against various types of tumors.

Regarding vaccination to prevent cancer, immunology experts recalled that there are currently two vaccines, one is the human papillomavirus (HPV) vaccine, which can cause a variety of cancers in men and women; the other is the hepatitis B vaccine, which can cause liver cancer.

Furthermore, he explained A vaccine against Epstein-Barr virus, an infection that causes many complications and is linked to all types of cancer, would represent a “significant leap forward.”

Gómez Rial presented the data at the XX International Vaccine Update Conference, which also analyzed topics such as news about the anti-flu campaign, the future of meningococcal vaccination or changes in the children’s calendar, EFE reported.